Amgen Posts Lower Aranesp Sales

August 2007
Bioworld Week;8/6/2007, Vol. 15 Issue 32, p2
The article reports on the decline of worldwide sales of Aranesp drug from Thousand Oaks, California-based Amgen Inc. as of the second quarter of 2007. According to Amgen, the 10% decrease of Aranesp worldwide sales was due to the reimbursement issues related to the anemia drug and the drop of U.S. demand for drug, in which the U.S. Aranesp reported sales in the second quarter of 2007 was only $578 million from $713 million in 2006.


Related Articles

  • Aranesp approved for extended dosing by in Europe.  // PharmaWatch: Biotechnology;November 2004, Vol. 3 Issue 11, p9 

    Announces that the European Commission has approved expanded marketing authorization for Aranesp, the anemia treatment of biotechnology firm Amgen, in the European Union. Extension of Aranesp dosing intervals of once-every-three-weeks in the treatment of anemia in adult cancer patients with...

  • Amgen to Pay $762 Million for Misbranding Anemia Drug Aranesp.  // MondayMorning;12/24/2012, Vol. 20 Issue 49, p1 

    The article informs about the prosecutors of Brooklyn federal court who has approved a payment of 762 million U.S. dollars from Amgen Inc. in order to resolve the civil cases against the company. It informs about payment to be paid in the lieu of resolving the criminal and civil cases related to...

  • Amgen's Anemia Drug Sales Miss 4Q Estimates.  // MondayMorning;2/2/2009, Vol. 17 Issue 4, p1 

    The article reports on the lower sales of the anemia drug of Amgen Inc. in the fourth quarter of 2008. It stated that the lower sales of the drug were offset by the increased sales of its rheumatoid arthritis therapy and is white-blood-cell booster, Neulasta. Its executives and analysts have...

  • Amgen's Epogen Successor Aranesp Gets FDA Approval. Krause, Carey // Chemical Market Reporter;9/24/2001, Vol. 260 Issue 11, p14 

    Reports on the approval of the U.S. Food and Drug Administration for Aranesp the successor to the anemia drug Epogen from Amgen. Forecast of financial analysts on Aranesp; Plan of Amgen to submit a biologics license supplement for Aranesp; Share of Amgen in the U.S. dialysis market.

  • Affymax Clearing Pathway For Hematide In 'Murky' ESA Space. Boggs, Jennifer // BioWorld Today;7/17/2007, Vol. 18 Issue 137, p1 

    This article reports on the decision of Affymax, Inc. to proceed with a Phase III program of its anemia drug Hematide in chronic renal failure patients. Patients on dialysis and those who are not will be enrolled by the company in four concurrent, open-label, randomized trials to evaluate the...

  • Panel Backs Use of Aranesp in Nondialysis CKD.  // Bioworld Week;10/25/2010, Vol. 18 Issue 43, p2 

    The article reports on the support of the panel of U.S. Food and Drug Administration (FDA) to the use of Aranesp of Amgen Inc. as a treatment for anemia in patients with chronic kidney disease (CKD).

  • Amgen closer to EU marketing approval for anemia drug.  // PharmaWatch: Biotechnology;September 2004, Vol. 3 Issue 9, p13 

    Reports that near-marketing authorization to be achieved by Amgen in Europe for its anemia treatment, Aranesp, following the recommendation of the European Committee for Medicinal Products for Human Use. Dose administration of the drug; Significant benefits to be provided by Aranesp for cancer...

  • New blood-boosting drugs aim to staunch renal anemia. Moyer, Melinda Wenner // Nature Medicine;Mar2012, Vol. 18 Issue 3, p332 

    The article reports on the development of drugs for the treatment of renal anemia in dialysis patients in the U.S. Aranesp (darbepoetin) from Amgen Inc. is the only longer-lasting analog of erythropoietin that is approved by the U.S. Food and Drug Administration (FDA). The development of...

  • Mixed Reviews For FDA Vote On Anemia Drugs.  // Bioworld Week;9/17/2007, Vol. 15 Issue 38, p4 

    The article presents information on a discussion about anemia drugs by a U.S. federal advisory panel for Amgen Inc. of California and the company Ortho Biotech of New Jersey. The U.S. Food and Drug Administration wanted to know about product labeling for erythropoiesis-stimulating agents (ESAs)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics